Metastatic pancreatic adenocarcinoma: Real-world efficacy of first line treatment

Gastrointestinal Cancer

First-line treatment efficacy of anti-EGFR versus anti-VEGF antibodies in BRAF(V600E)-mutated metastatic colorectal cancer according to primary tumor sidedness: A pooled analysis of seven clinical trials performed in the first-line treatment of mCRC (German AIO Study Group)

Eur J Cancer

Weiss L, Stintzing S, Modest DP, Stahler A, von Weikersthal LF, Reinacher-Schick A, Decker T, Probst V, Heinrich K, Schwaner I, Kaiser F, Pihusch R, Fuchs M, Held S, Alig A, Gruenberger B, Prager GW, Tougeron D, Taieb J, Heinemann V

doi: 10.1016/j.ejca.2025.116105

Gastrointestinal Cancer

Real-World Analysis of Irinotecan With or Without Fluorouracil in the Second-Line Treatment of Metastatic Colorectal Cancer

J Natl Compr Canc Netw

Lentz RW, Hu J, Robinson H, Balmaceda N, Baiyee E, Leal AD, Kim SS, Davis SL, Messersmith WA, Lieu CH

doi: 10.6004/jnccn.2025.7031

Inflammatory Bowel Disease

Treatment sequences, outcomes, healthcare utilization, and costs in patients with inflammatory bowel diseases requiring advanced treatment-real world comparative effectiveness from German claims data

BMC Gastroenterol

Dignass A, Teich N, Kaiser S, Sünwoldt J, Dünweber C, Weinhold I, Borchert J, Kudernatsch R

doi: 10.1186/s12876-025-04022-7

Helicobacter Pylori

Efficacy and Safety of Levofloxacin- Versus Moxifloxacin-Based Nitazoxanide Quadruple Therapy as Second-Line Treatment for Helicobacter pylori in Egypt: A Randomized Multicenter Trial

Helicobacter

El-Azab G, Abdel Salam S, Moustafa E, Abuoelhassan A, Shamseya A, Ellakany A, Abdelaal U, Assem M, Khalil F, Mahmoud A, Elsabaawy M, Hussein B, Ezz-Eldin M, Hassany S, Zaghloul N, Magdy M

doi: 10.1111/hel.70104

Gastrointestinal Cancer

Comparative Efficacy and Safety of Tislelizumab in Second-Line Esophageal Squamous Cell Carcinoma: Systematic Literature Review and Simulated Treatment Comparisons

Adv Ther

Ajani JA, Wang K, Nikolaidis GF, Coaquira Castro J, Augusto Novis de Figueiredo M, Sun JM, Soulanis K, Tasoulas A, Zhan L

doi: 10.1007/s12325-025-03410-5

Inflammatory Bowel DiseaseFurther Publications

Filgotinib Is an Effective and Safe Treatment Option for Difficult-To-Treat Ulcerative Colitis: Real-World Evidence of the Dutch Initiative on Crohn and Colitis (ICC) Registry

United European Gastroenterol J

Naber MR, van der Meulen AE, Voorneveld PW, Veltkamp SHC, van Bodegraven AA, Bodelier A, Mujagic Z, Pierik M, Verleye LMM, Duijvestein M, Bouwknegt DG, Visschedijk MC, Srivastava N, West RL, Oldenburg B, Löwenberg M, van Schaik FDM, Dutch ICC Registry

doi: 10.1002/ueg2.70141

Further Publications

Efficacy and safety of vedolizumab in elderly and younger patients with moderate-to-severe ulcerative colitis: a retrospective real-world study in China

BMC Gastroenterol

Zhang H, Ding XL, Xu YH, Wu J, Wang YY, Liu SX, Yan J, Liu H, Tian ZB, Liu AL

doi: 10.1186/s12876-025-04125-1

Inflammatory Bowel Disease

A Real-World Longitudinal Case-Study Implementing Digital Screening and Treatment for Distress in Inflammatory Bowel Disease: The COMPASS-IBD Patient Journey

Inflamm Bowel Dis

Jones ASK, Seaton N, Harding S, Duff A, Hudson J, Wroe A, Norton S, Singh H, Onih J, Moss-Morris R

doi: 10.1093/ibd/izaf259

Gastrointestinal Cancer

Trastuzumab Deruxtecan Versus Ramucirumab-Paclitaxel as Second-Line Therapy for Patients With HER2-Positive Gastric or GEJ Adenocarcinoma

J Natl Compr Canc Netw

Verhoeven RHA, Kuijper SC, Lordick F, Slingerland M, Qin A, van Laarhoven HWM

doi: 10.6004/jnccn.2025.7058

Related content

First-line treatment efficacy of anti-EGFR versus anti-VEGF antibodies in BRAF(V600E)-mutated metastatic colorectal cancer according to primary tumor sidedness: A pooled analysis of seven clinical trials performed in the first-line treatment of mCRC (German AIO Study Group)

Real-World Analysis of Irinotecan With or Without Fluorouracil in the Second-Line Treatment of Metastatic Colorectal Cancer

Treatment sequences, outcomes, healthcare utilization, and costs in patients with inflammatory bowel diseases requiring advanced treatment-real world comparative effectiveness from German claims data

Efficacy and Safety of Levofloxacin- Versus Moxifloxacin-Based Nitazoxanide Quadruple Therapy as Second-Line Treatment for Helicobacter pylori in Egypt: A Randomized Multicenter Trial

Comparative Efficacy and Safety of Tislelizumab in Second-Line Esophageal Squamous Cell Carcinoma: Systematic Literature Review and Simulated Treatment Comparisons

Filgotinib Is an Effective and Safe Treatment Option for Difficult-To-Treat Ulcerative Colitis: Real-World Evidence of the Dutch Initiative on Crohn and Colitis (ICC) Registry

Efficacy and safety of vedolizumab in elderly and younger patients with moderate-to-severe ulcerative colitis: a retrospective real-world study in China

A Real-World Longitudinal Case-Study Implementing Digital Screening and Treatment for Distress in Inflammatory Bowel Disease: The COMPASS-IBD Patient Journey

Trastuzumab Deruxtecan Versus Ramucirumab-Paclitaxel as Second-Line Therapy for Patients With HER2-Positive Gastric or GEJ Adenocarcinoma